ReviewFrontiers in cellular and infection microbiology2026
The microbiota-host metabolic axis in cervical cancer: from homeostatic disruption to mechanisms of therapy resistance.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent infection with high-risk human papillomavirus (HR-HPV) is a prerequisite for cervical carcinogenesis. In this process, the vaginal microbiota, as a key component of the cervical microenvironment, plays a significant role in facilitating viral persistence and malignant transformation. Moving beyond the conventional focus on compositional shifts, this review systematically examines the dynamic remodeling of the host-microbiota co-metabolic network during the progression from health to invasive cervical cancer. It explores in depth the interactive mechanisms through which metabolites derived from a dysbiotic microbiota exacerbate epithelial barrier damage, modulate local immune evasion, and activate oncogenic signaling pathways, with particular emphasis on how co-metabolic imbalance drives therapeutic resistance. By integrating these insights, this review aims to advance the mechanistic understanding of microbial contributions to cervical cancer development and to inform novel strategies for overcoming treatment resistance through microbiota-targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.